WO2008061674A3 - Use of an animal model and method for testing drugs and treatments for cancer in humans - Google Patents

Use of an animal model and method for testing drugs and treatments for cancer in humans Download PDF

Info

Publication number
WO2008061674A3
WO2008061674A3 PCT/EP2007/009911 EP2007009911W WO2008061674A3 WO 2008061674 A3 WO2008061674 A3 WO 2008061674A3 EP 2007009911 W EP2007009911 W EP 2007009911W WO 2008061674 A3 WO2008061674 A3 WO 2008061674A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
humans
treatments
animal model
animal
Prior art date
Application number
PCT/EP2007/009911
Other languages
French (fr)
Other versions
WO2008061674A2 (en
Inventor
Gerardus Johannes Mari Martens
Original Assignee
Synthon Bv
Loo Karen Miriam Johanna Van
Gerardus Johannes Mari Martens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv, Loo Karen Miriam Johanna Van, Gerardus Johannes Mari Martens filed Critical Synthon Bv
Publication of WO2008061674A2 publication Critical patent/WO2008061674A2/en
Publication of WO2008061674A3 publication Critical patent/WO2008061674A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to the use of a non-human animal in an animal model for studying cancer and/or for assaying novel treatments and drugs for treating cancer in humans, which animal has an alteration in its genome as compared to the wildtype animal, which alteration leads to a modified expression of Aph-1b. The alteration comprises for example the presence of only one copy of the Aph-1b gene as compared to two copies in the wild type genome or the presence of the SNP651 T>G mutation in the said gene.
PCT/EP2007/009911 2006-11-24 2007-11-08 Use of an animal model and method for testing drugs and treatments for cancer in humans WO2008061674A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2006011267 2006-11-24
EPPCT/EP2006/0112 2006-11-24

Publications (2)

Publication Number Publication Date
WO2008061674A2 WO2008061674A2 (en) 2008-05-29
WO2008061674A3 true WO2008061674A3 (en) 2008-07-31

Family

ID=39402770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/009911 WO2008061674A2 (en) 2006-11-24 2007-11-08 Use of an animal model and method for testing drugs and treatments for cancer in humans

Country Status (1)

Country Link
WO (1) WO2008061674A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2495059A (en) 2010-07-23 2013-03-27 Pro Cure Therapeutics Ltd Mammalian model for amplification of cancer stem cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028655A2 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Drug discovery for neurodevelopmental disorders and their complications
WO2007028631A1 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Genetic risk factor for neurodevelopmental disorders and their complications
WO2007028656A2 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Animal model and method for testing drugs and treatments for neurodevelopment disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028655A2 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Drug discovery for neurodevelopmental disorders and their complications
WO2007028631A1 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Genetic risk factor for neurodevelopmental disorders and their complications
WO2007028656A2 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Animal model and method for testing drugs and treatments for neurodevelopment disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COOLEN M W ET AL: "Ontogenic reduction of Aph-1b mRNA and gamma-secretase activity in rats with a complex neurodevelopmental phenotype.", MOLECULAR PSYCHIATRY AUG 2006, vol. 11, no. 8, August 2006 (2006-08-01), pages 787 - 793, XP002482399, ISSN: 1359-4184 *
COOLEN M W ET AL: "REDUCED APH-1B EXPRESSION CAUSES TISSUE- AND SUBSTRATE-SPECIFIC CHANGES IN GAMMA-SECRETASE ACTIVITY IN RATS WITH A COMPLEX PHENOTYPE", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, no. 12, 25 October 2005 (2005-10-25), pages 1 - 15, XP008061282, ISSN: 0892-6638 *
COOLEN MARCEL W ET AL: "Gene dosage effect on gamma-secretase component Aph-1b in a rat model for neurodevelopmental disorders", NEURON, CELL PRESS, vol. 45, no. 4, 17 February 2005 (2005-02-17), pages 497 - 503, XP002474139, ISSN: 0896-6273 *
MIELE L ET AL: "NOTCH SIGNALING AS A NOVEL CANCER THERAPEUTIC TARGET", CURRENT CANCER DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 6, no. 4, 1 June 2006 (2006-06-01), pages 313 - 323, XP009073569, ISSN: 1568-0096 *
POLI MAURA ET AL: "Association analysis between anterior-pharynx defective-1 genes polymorphisms and Alzheimer's disease", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 350, no. 2, 23 October 2003 (2003-10-23), pages 77 - 80, XP002474140, ISSN: 0304-3940 *

Also Published As

Publication number Publication date
WO2008061674A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2007127190A3 (en) Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice
WO2008030892A3 (en) Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
BRPI0709598A8 (en) stabilized polypeptide compositions
EP2321430B8 (en) Method of evaluating oral cancer risk in human
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
WO2005007869A3 (en) Assays for the direct measurement of gene dosage
WO2008144761A3 (en) Methods and compositions for identifying and treating lupus
WO2007111938A3 (en) Inflammation-inhibitory serum factors and uses thereof
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2006078648A3 (en) Rhinovirus vaccines
WO2009030770A3 (en) Methods and tools for prognosis of cancer in er- patients
EA200970407A1 (en) INHIBITORS KINAZ MAPK / ERK
Gurbanov et al. Aspects of silver tolerance in bacteria: infrared spectral changes and epigenetic clues
GB2450843B (en) Mutant HSV, materials and methods for generation of mutant HSV
WO2007002587A3 (en) Inhibitors of epstein barr virus nuclear antigen 1
HK1112928A1 (en) Cspcna isoform modifications and uses thereof
WO2008061674A3 (en) Use of an animal model and method for testing drugs and treatments for cancer in humans
MX2011007989A (en) Markers to predict and monitor response to aurora kinase b inhibitor therapy.
WO2009145830A3 (en) Signatures of radiation response
WO2007035962A3 (en) Gene blocking method
WO2008140483A3 (en) Methods and antibodies for detecting protective antigen
WO2007028656A3 (en) Animal model and method for testing drugs and treatments for neurodevelopment disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07846620

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07846620

Country of ref document: EP

Kind code of ref document: A2